Objective: To observe the effects of transforming growth factor-β1 (TGF-β1) and atorvastatin on expressions of collagen type I P-Smad2, Smad4 and Smad7 in human atrial ifbroblasts, and to explore the ifbrosis and anti-ifbrosis mechanisms in human atrium. Methods: Human right atrial appendage tissue was obtained from the cardiac surgery in our hospital and the atrial ifbroblasts were isolated and cultured by generations. The effects of TGF-β1 and atorvastatin on atrial ifbroblast proliferation was detected by MTT method and the effect of TGF-β1 at (0, 0.1, 1.0, 5.0, 10.0, 20.0, 50.0) ng/ml and atorvastatin at (0, 0.1, 1.0, 10.0, 100.0) μmol/L on mRNA and protein expressions of collagen type I P-Smad2, Smad4 and Smad7 in atrial ifbroblasts were examined by RT-PCR and Western-blotting analysis respectively. Results: MTT detection presented that compared to TGF-β1 at 0 ng/ml, with the intervention of TGF-β1 at (1 and 10) ng/ml, the mRNA and protein expressions of collagen type I P-Smad2, Smad4 increased,P<0.05 and the expressions of Smad7 decreased,P<0.05. Compared to TGF-β1 at 10.0 ng/ml, with the intervention of TGF-β1 + atorvastatin at 10.0 μmol/L or with atorvastatin at 10.0 μmol/L alone, the mRNA and protein expressions of collagen type I P-Smad2, Smad4 decreased,P<0.05and expressions of Smad7 increased,P<0.05. Conclusion: TGF-β1 promotes human atrial ifbroblast proliferation and collagen type I expression, while atorvastatin inhibits such proliferation and expression, the effect might be done by affecting TGF-β1/Smads pathway in human atrial ifbroblasts.

HPLC is widely applied in the analysis of chemical drugs. In order to regulate the use and maintenance of HPLC col-umn and guarantee the analysis quality of HPLC, the classified management of HPLC column was explored in the paper from the follow-ing five aspects:file establishment, recipient and return management, column performance evaluation, information accumulation of ap-plication range, and maintenance and abandonment of HPLC column.

The Pharmacopeia of the People’s Republic of China 2025 Edition (referred to as the Chinese Pharmacopoeia 2025 Edition, ChP 2025) will be promulgated and implemented. This article introduces the process of development of ChP 2025 Edition (Volume Ⅱ), including the selection, the revision of general notices,the addition and revision of drug monographs, etc., and provides some analysis and examples to illustrate,which can facilitate the readers to understand and implement the ChP 2025 Edition (Volume Ⅱ).